References:

  • Bazzani C, et al. 2015. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clin Exp Rheumatol; 33(5):688-93.
  • Berthelsen BG, et al. 2010. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford); 49:2225-7.
  • Brӧms G, et al. 2016. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clinical Gastroenterology and Hepatology 14(2):234-241.e5.
  • Carman WJ, et al. 2017. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 26:1109-1118.
  • Carter JD, et al. 2009. A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database. The Journal of Rheumatology 36:3.
  • Carter JD, et al. 2006. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33(5):1014-7.
  • Chambers CD, et al. 2004. Pregnancy outcome in women exposed to anti-TNF-alpha medications: The OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum 50(9):S479-S480.
  • Chambers CD, et al. 2015. Pregnancy outcomes in women exposed to etanercept: the OTIS autoimmune diseases in pregnancy project. Abstract presented at Annual Meeting, Am College of Rheum, San Francisco, CA, November 6th-11th.
  • Clark, DA. 2010. Anti-TNF_ therapy in immune-mediated subfertility: State of the art. J Reprod Immunol 85(1):15-24.
  • Dall’ara F, et al. 2016. Safety of anti-TNF alfa agents during pregnancy and breastfeeding: longterm follow up of exposed children in a case-series of mothers with chronic arthritides. Ann Rheum Dis 75(Suppl 2): 493.
  • Diav-Citrin O, et al. 2014. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study. Reprod Toxicol 43:78-84.
  • Johnson DL, et al. 2008. Pregnancy Outcomes in Women Exposed to Etanercept: The OTIS Autoimmune Diseases in Pregnancy Project [abstract]. Arthritis and Rheumatism 58(9):S682.
  • Keeling S and Wolbink GJ. 2010. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. J Rheumatol 37(7):1551.
  • Micu MC, et al. 2014. TNF-alpha inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment Rheumatology (Oxford). 53(7):1250-5.
  • Ӧnalan G, et al. 2017. Effect of etanercept on the success of assisted reproductive technology in patients with endometrioma. Gynecol Obstet Invest. PMID:
  • Orozco C, et al. 2005. Safety of TNF inhibitors during pregnancy in patients with inflammatory arthritis. Abstract presented at 69th Annual Meeting, Am College of Rheum, San Diego, CA, November 13th-17th.
  • Pentsuk N and van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 86(4):328-44.
  • Roux CH, et al. 2006. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{alpha} therapy. Rheumatology 46: 695-698.
  • Verstappen SM, et al. 2011. BSRBR Control Centre Consortium, BSR Biologics Register. Concise report: anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 70(5): 823-826.
  • Villiger PM, et al. 2010. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10): 1842-4.
  • Viktil KK, et al. 2012. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scandinavian Journal of Rheumatology, 41(3): 196-201.
  • Weber-Schoendorfer C, et al. 2015. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 80(4): 727-39